menu
    • menu
    [{"orgOrder":0,"company":"EQRx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Sugemalimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EQRx","amount2":1.3,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Intravenous Infusion","sponsorNew":"EQRx \/ EQRx","highestDevelopmentStatusID":"15","companyTruncated":"EQRx \/ EQRx"},{"orgOrder":0,"company":"EQRx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EQRx \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"EQRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"Sugemalimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Intravenous Infusion","sponsorNew":"EQRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Undisclosed"},{"orgOrder":0,"company":"EQRx","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Aumolertinib Mesylate","moa":"EGFR*","graph1":"Oncology","graph2":"Approved FDF","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ EQRx","highestDevelopmentStatusID":"15","companyTruncated":"EQRx \/ EQRx"},{"orgOrder":0,"company":"EQRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"Abdul Latif Jameel Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Aumolertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Abdul Latif Jameel Health","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Abdul Latif Jameel Health"},{"orgOrder":0,"company":"EQRx","sponsor":"CM Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Aumolertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":2,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ CM Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ CM Life Sciences"},{"orgOrder":0,"company":"EQRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aumolertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"EQRx","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EQRx \/ EQRx","highestDevelopmentStatusID":"4","companyTruncated":"EQRx \/ EQRx"},{"orgOrder":0,"company":"EQRx","sponsor":"Aurigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EQRx \/ EQRx","highestDevelopmentStatusID":"2","companyTruncated":"EQRx \/ EQRx"},{"orgOrder":0,"company":"EQRx","sponsor":"GOG Foundation | European Network for Gynaecological Oncological Trial Groups","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lerociclib","moa":"cyclin dependent kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EQRx \/ GOG Foundation | European Network for Gynaecological Oncological Trial Groups","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ GOG Foundation | European Network for Gynaecological Oncological Trial Groups"},{"orgOrder":0,"company":"EQRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lerociclib","moa":"cyclin dependent kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EQRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EQRx \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EQRx \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"EQRx \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by EQRx

    Menu

    EQRx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Revolution Medicines Completes Acquisition of EQRx

                            Details : Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 11, 2023

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : GOG Foundation | European Network for Gynaecological Oncological Trial Groups

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metast...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 06, 2023

                            Lead Product(s) : Lerociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : GOG Foundation | European Network for Gynaecological Oncological Trial Groups

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More than $1 Billion in Addi...

                            Details : Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 08, 2023

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Rec...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 09, 2022

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Aurigene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnershi...

                            Details : Under the terms of the collaboration agreement, Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 07, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Aurigene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

                            Details : Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 29, 2022

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Insilico Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Dev...

                            Details : The collaboration will combine Insilico's Pharma.AI platform to advance de novo small molecule design and generation with EQRx's clinical development and commercialization expertise.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 24, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Insilico Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 20, 2022

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sugemalimab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natur...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 23, 2021

                            Lead Product(s) : Sugemalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Abdul Latif Jameel Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in...

                            Details : Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 22, 2021

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Abdul Latif Jameel Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth